A subsequent trial analyzed the efficacy of the combination between gemcitabine and erlotinib versus gemcitabine alone depending on the presence of EGFR mutations among 88 chemotherapy-naïve metastatic PC patients [64]. This evidence concerns the gene EGFR and pachyonychia congenita.